Patients' Understanding of How Genotype Variation Affects Benefits of Tamoxifen Therapy for Breast Cancer
- Brewer, N.T.
- DeFrank, J.T.
- Chiu, W.K.
- Ibrahim, J.G.
- Walko, C.M.
- Rubin, P.
- Olajide, O.A.
- Moore, S.G.
- Raab, R.E.
- Carrizosa, D.R.
- Corso, S.W.
- Schwartz, G.
- Peppercorn, J.M.
- McLeod, H.L.
- Carey, L.A.
- Irvin, W.J.
Publication date
January 2014
DOIAbstract
CYP2D6 is a critical enzyme in the metabolism of tamoxifen and potentially a key determinant in breast cancer outcomes. Our study examined patients' beliefs about how CYP2D6 genotype would affect their prognoses
Add to ORKG